SCHEMBL4904647

SCHEMBL4904647

CCCC(CCC)C(=O)NC(=O)c1nc(-c2ccc(Cl)cc2Cl)n(-c2ccc(Cl)cc2)c1C

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 19/20 0.62
CNR2 P34972 18/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907050 0.92 CNR1 (0.64) CNR1CNR2
SCHEMBL4910650 0.91 CNR1 (0.59) CNR1CNR2
SCHEMBL4906941 0.81 CNR1 (0.67) CNR1CNR2
SCHEMBL4904066 0.81 CNR1 (0.72) CNR1CNR2
SCHEMBL4506215 0.80 CNR1 (0.76) CNR1CNR2
SCHEMBL6700221 0.78 CNR1 (0.69) CNR1CNR2
SCHEMBL4517938 0.78 CNR1 (0.79) CNR1CNR2
SCHEMBL3680322 0.77 CNR1 (0.71) CNR1CNR2
SCHEMBL1040785 0.77 CNR1 (0.74) CNR1CNR2
SCHEMBL4905874 0.77 CNR1 (0.75) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262066-A1 Azole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-10-23 US claimed
US-20080262066-A1 Azole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-10-23 US disclosed
US-20080262066-A1 Azole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-10-23 US disclosed
US-20080262066-A1 Azole Derivatives as Cannabinoid CB1 Receptor Antagonists GREEN CROSS CORPORATION (KR) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262066-A1 Azole Derivatives as Cannabinoid CB1 Receptor Antagonists CNR1, CNR2, GPR119 CNR1 1/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.